Vitamin K intake and stability of oral anticoagulant treatment

• References

• 1 Campbell E, Link KP. Studies on the haemorrhagic sweet clover disease. J Biol Chem 1941; 138: 21-33.
• 2 Butt HR, Allen AV, Bollman JR. A preparation from spoiled sweet clover which prolongs coagulation toime and prothrombin time of blood. Proc Staff Meet Mayo Clin 1941; 16: 388-95.
• 3 Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2: 2118-32.
• 4 Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood 1999; 93: 1798-808.
• 5 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
• 6 Li T, Chang CY, Jin DY. et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
• 7 Booth SL, O’Brien-Morse ME, Dallal GE. et al. Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults. Am J Clin Nutr 1999; 70: 369-77.
• 8 Margaglione M, Colaizzo D, Andrea G. et al. Genetic modulation of oral anticoagulationwith warfarin. Thromb Haemost 2000; 84: 775-8.
• 9 D'Andrea G, D'Ambrosio RL, Di Perna P. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
• 10 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study(ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
• 11 Sconce E, Khan T, Mason J. et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93: 872-5.
• 12 Schurgers LJ, Shearer MJ, Halmujak K. et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104: 2682-9.
• 13 Hallgren KW, Hommema EL, McNally BA. et al. Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. Biochemistry 2002; 41: 15045-55.
• 14 Wajih N, Sane DC, Hutson SM. et al. Engineering of a recombinant vitamin K-dependent γ-carboxylation system with enhanced γ-carboxyglutamic acid forming capacity: Evidence for a functional CXXC Red Ox center in the system. J Biol Chem 2005; 280: 10540-7.
• 15 Oldenburg J, Quenzel EM, Harbrecht U. et al. Missense mutation at Ala-10 in the factor IX-propeptide: An insignificant variant in normal life but a decisive cause for bleeding duringoral anticoagulant therapy. Br J Haematol 1997; 98: 240-4.